Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.
Assistance Publique - Hôpitaux de Paris
200 participants
Feb 2, 2026
INTERVENTIONAL
Conditions
Summary
In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included. 600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset. Besides the standard of care, blood samples will be collected. All data collected will be stored in an onlie Castor database
Eligibility
Inclusion Criteria5
- Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma
- Adults aged 18 years or over
- Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging
- Patient who has signed a consent form to participate in the study
- Patient who is a beneficiary of a social security scheme or who is entitled to it
Exclusion Criteria8
- Any systemic or ocular pathologies with an impact on the posterior segment of the eye
- Patient with a systemic pathology likely to affect the posterior segment of the eye:
- Diabetes
- Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease
- Patients with retinitis pigmentosa
- Patients with syndromic myopia
- Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy
- Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood sampling for DNA and serum and plasma colection and PBMC
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06949579